Life science biotechnology company specializing on using naturally extracted psilocybin for long-term treatment of trauma and its mental health results Psyence Group Inc. (CSE: PSYG) (OTCQB: PSYGF) announced having receives International Organization for Standardization (ISO) 22000:2018 certification for its ISO22000 graded psilocybin production facility.
This certification was awarded through British Standards Institute (BSI). ISO 22000 is a global accepted international standard which highlights the requirements for food safety management systems.
The company’s psilocybin production facility is located in Southern Africa and has been licensed by federal authorities to cultivate and export psilocybin mushrooms for the legal medical and research markets. The facility has been operating since January 2021.
The facility was designed and constructed under the ISO 14644-1 cleanroom specifications and engineering design principles. The design allows various parts to comply with the Good Manufacturing Practice (GMP) Standards required for product safety and quality so as to meet the certification requirements of the BSI.
Following this certification, Psyence has inched closer to producing pharmaceutical grade product for human clinical trials including its own clinical trial on palliative care and others conducted by other research organizations.
“As a science led company we are committed to producing high quality, natural psilocybin. ISO22000: 2018 certification gives our drug development partners and, ultimately, consumers, assurance that our production processes meet globally recognized standards. With this certification awarded by the BSI we are reassured that our equipment and processes are performing to the high standards required by the BSI, that our staff are skilled and experienced, and that our standard operating procedures are efficient and validated,” said the company’s chief strategy officer, Tony Budden.